Tag: preclinical
-
Strategy Proposed for Overcoming Resistance to Cancer Drug
Researchers in the U.K., with colleagues from the U.S. and Sweden, have recommended a way to overcome the resistance of cancer cells to the drug crizotinib, which recently showed positive results in its first trial in children with cancer. The findings are published online this week in the journal Cancer Cell (paid subscription required). Louis…
-
Lundbeck, Foundation to Partner on Huntington’s Research
The U.S. subsidiary of the pharmaceutical company Lundbeck A/S and the CHDI Foundation in Los Angeles will collaborate on research for a targeted therapy for Huntington’s Disease. Financial terms of the agreement were not disclosed. Huntington’s disease is an inherited disease that causes the progressive degeneration of nerve cells in the brain, affecting a person’s…
-
Cancer Stem Cell Drug Screening Chip Developed
Researchers at the Institute of Bioengineering and Nanotechnology (IBN) in Singapore have developed a miniaturized biochip for investigating the effect of drugs on cancer stem cells. The findings of the team led by IBN executive director Jackie Ying appears the journal Nano Today, and the technology is being commercialized by a spin-off company from the…
-
Eye Treatment Delivery Option to Syringe Being Developed
Engineers at McMaster University in Hamilton, Ontario, Canada have developed a new system using an implanted patch to deliver drugs to the back of the eye, as an alternative to direct injection with a syringe. The results of their research appear online in the Journal of Biomaterials Applications (paid subscription required). The team led by…
-
Consortium Develops Virtual Mouse for Lab Testing
Simcyp Ltd. in Sheffield, U.K., a consortium of pharmaceutical and biotech companies and research universities, has created a virtual lab mouse for use in cancer and toxicological research. Simcyp is a spin-off enterprise from Sheffield University that develops modeling and simulation tools for lab testing. Lab mice are used frequently in the development of new drugs…
-
U.S. Patent Granted for Peptide-Based Obesity Treatment
Unigene Laboratories Inc. in Boonton, New Jersey has received a patent for its appetite suppression technology used in the treatment of obesity. Patent no. 8,076,291 from the United States Patent and Trademark Office was issued on 13 December 2011. The patent protects the company’s compounds that work like the hormone calcitonin to reduce the appetite…
-
Ophthalmology Drug Delivery Start-Up Gets $4M Investment
An Atlanta-based start-up, Clearside Biomedical, has received a $4 million venture capital investment from Hatteras Venture Partners in Research Triangle Park, North Carolina. Clearside Medical is commercializing technology developed at Emory University and Georgia Tech that delivers drugs to precise locations in the eye using hollow microneedles. Research behind the Clearside Biomedical technology was conducted…
-
U.S. Patent Granted for Soft Tissue Reconstruction Implant
The U.S. Patent and Trademark Office has awarded a patent to Novus Scientific in Singapore for a resorbable mesh implant to be used in the reconstruction of soft tissue defects. The patent — number 8,083,755 — covers the mesh implant material that breaks down and is assimilated back into the body. Novus Scientific developed the…
-
Protein Discovered That Enables Heart Tissue Repair
Researchers at the Max Planck Institute for Heart and Lung Research in Bad Nauheim, Germany have found a protein that stimulates regression of individual heart muscle cells into their precursor cells, a step required for self-generated healing of damaged heart tissue. The Max Planck Institute, with colleagues from the Schüchtermann Klinik in Bad Rothenfelde, published…
-
NIH Awards Infectious Disease Therapy Contracts
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, awarded contracts totaling $37.5 million to five companies to develop therapies for diseases caused by multiple types of bacteria or viruses. The five-year orders, with a potential total value of $150 million, cover research to extend promising drug candidates…